Members |
targetComponentId |
patienten gennemgået på hospitalet |
Review at hospital (procedure) |
Patient self-deregistration NOS |
Patient deregistration status |
Patient self-deregistration NOS |
Patient self-deregistration |
Patient temp. away NOS |
Patient temporarily left |
Patient temp. away NOS |
Patient temporarily left |
Patientudløst inspiratorisk assistance |
Pressure support ventilation (regime/therapy) |
Patient written birth plan |
Patient written birth plan (record artifact) |
diæt indledt af patient, ikke nærmere specificeret |
Patient-initiated diet |
Patient-initiated diet NOS |
Patient-initiated diet |
Patient-initiated encounter NOS |
Patient encounter status |
Patient-initiated encounter NOS |
Patient-initiated encounter |
pauciartikulær juvenil reumatoid artrit |
Oligoarticular juvenile idiopathic arthritis (JIA) affects between one and up to a maximum of four joints. |
Pauciarticular onset juvenile chronic arthritis |
Oligoarticular juvenile idiopathic arthritis (JIA) affects between one and up to a maximum of four joints. |
Peaceful environment |
Peaceful environment (finding) |
Peach - dietary |
Peach (substance) |
Peanut - dietary |
Peanut (substance) |
Pear - dietary |
Pear (substance) |
Pectobacterium chrysanthemi |
Dickeya chrysanthemi (organism) |
Pectoralis major myocutaneous flap plus rib |
Pectoralis major osteomyocutaneous flap of rib |
rasttest med fødevareblanding til børn |
Food mix specific IgE antibody measurement |
Pedicle flap reconstruction - action |
Flap reconstruction - action |
Pedicle transverse rectus abdominus flap |
Pedicle transverse rectus abdominis myocutaneous flap (substance) |
Pediculus humanus humanus |
Pediculus humanus |
Pediococcus urinae-equi |
Aerococcus urinaeequi (organism) |
peeling - handling |
Stripping - action |
pegaptanib 0,3 mg injektionsvæske, opløsning i fyldt injektionssprøjte a 1 ml |
Pegaptanib (as pegaptanib sodium) 3.33 mg/mL solution for injection |
peginterferon alfa-2a 135 µg/0,5 ml injektionsvæske, opløsning i fyldt injektionssprøjte |
Product containing precisely interferon alfa-2a (as peginterferon alfa-2a) 270 microgram/1 milliliter conventional release solution for injection (clinical drug) |
peginterferon alfa-2a 180 µg/0,5 ml injektionsvæske, opløsning i fyldt injektionssprøjte |
Interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/mL solution for injection |
peginterferon alfa-2b 100 µg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Interferon alfa-2b (as peginterferon alfa-2b) 100 microgram powder for solution for injection vial |
Peginterferon alfa-2b 100micrograms powder for solution for injection in prefilled pen |
Peginterferon alfa-2b only product in parenteral dose form |
peginterferon alfa-2b 100 µg pulver + solvens til injektionsvæske, opløsning, fyldt pen |
Peginterferon alfa-2b only product in parenteral dose form |
peginterferon alfa-2b 120 µg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 120 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
peginterferon alfa-2b 120 µg pulver + solvens til injektionsvæske, opløsning, fyldt pen |
Interferon alfa-2b (as peginterferon alfa-2b) 120 microgram powder for solution for injection pen |
peginterferon alfa-2b 150 µg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
peginterferon alfa-2b 150 µg pulver + solvens til injektionsvæske, opløsning, fyldt pen |
Interferon alfa-2b (as peginterferon alfa-2b) 150 microgram powder for solution for injection pen |
peginterferon alfa-2b 50 µg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 50 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
peginterferon alfa-2b 50 µg pulver + solvens til injektionsvæske, opløsning, fyldt pen |
Interferon alfa-2b (as peginterferon alfa-2b) 50 microgram powder for solution for injection pen |
peginterferon alfa-2b 80 µg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 80 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
peginterferon alfa-2b 80 µg pulver + solvens til injektionsvæske, opløsning, fyldt pen |
Interferon alfa-2b (as peginterferon alfa-2b) 80 microgram powder for solution for injection pen |
Pegvisomant 30mg powder for injection solution vial |
Pegvisomant 20 mg powder for solution for injection vial |
Pelvic contrast radiography |
Plain X-ray of pelvis with contrast (procedure) |
radiografi med kontraststof af bækkenet |
Plain X-ray of pelvis with contrast (procedure) |
bækkenrømning, kvinde |
Pelvic exenteration |
Pelvic floor repair |
Repair of enterocele |
Pelvin lymfangiografi |
Fluoroscopic lymphangiography of pelvis with contrast (procedure) |
Pelvic lymphangiogram |
Fluoroscopic lymphangiography of pelvis with contrast (procedure) |
Pelvic lymphangiogram |
Fluoroscopic lymphangiography of pelvis with contrast (procedure) |
bilateral pelvin lymfangiografi |
Fluoroscopic lymphangiography of bilateral pelvis with contrast (procedure) |
røntgenundersøgelse af bløddele i bækkenområdet |
Plain X-ray of soft tissue of pelvis (procedure) |
Abnormitet i bløddele i bækkenet under graviditet, fødsel og puerperium med prænatalt problem |
Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium |
anormitet i bløddel i bækkenet under graviditet, fødsel og puerperium med postnatal komplikation |
Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium |
pelvin somatisk dysfunktion |
Impaired or altered function of related components of the body framework system: skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic and neural elements. It is characterized by positional asymmetry, restricted range of motion, tissue texture abnormalities, and/or tenderness. The positional and motion aspects of somatic dysfunction are generally described by: (1) The position of a body part as determined by palpation and referenced to its defined adjacent structure, (2) The directions in which motion is freer, and (3) The directions in which motion is restricted. Somatic dysfunction is treatable using osteopathic manipulative treatment. |
røntgenundersøgelse af bækkenet |
Plain X-ray of pelvis (procedure) |
penetrerende traumatisk læsion forårsaget af glas |
Penetrating injury caused by glass fragment |
traumatisk læsion forårsaget af penetrerende glas |
Penetrating injury caused by glass fragment |
Penetrating wound of orbit without mention of foreign body |
Penetrating wound of orbit |
Penetrating wound of orbit without mention of foreign body |
Penetrating wound of orbit |
Penicillin G benzathine 300,000unit/mL injection |
Product containing precisely benzathine benzylpenicillin 300000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
Penicillin antibacterial overdose |
Penicillin overdose |
benzylpenicillin, benzathin 150.000 IE + benzylpenicillin, procain 150.000 IE pulver til injektionsvæske, opløsning, hætteglas |
Product containing precisely benzathine benzylpenicillin 150000 unit/1 milliliter and procaine benzylpenicillin 150000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
Penicillin g benzathine 300,000unt/mL injection |
Product containing precisely benzathine benzylpenicillin 300000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
benzylpenicillin, benzathin 300.000 enheder/ml injektionsvæske, suspension, hætteglas a 10 ml |
Product containing precisely benzathine benzylpenicillin 300000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
benzylpenicillin, benzathin 300.000 enheder/ml injektionsvæske, suspension, hætteglas a 1 ml |
Product containing precisely benzathine benzylpenicillin 300000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
benzylpenicillin, benzathin 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 1 ml |
Benzathine benzylpenicillin 600000 unit/mL suspension for injection |
benzylpenicillin, benzathin 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 20 ml |
Benzathine benzylpenicillin 600000 unit/mL suspension for injection |
benzylpenicillin, benzathin 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 2 ml |
Benzathine benzylpenicillin 600000 unit/mL suspension for injection |
benzylpenicillin, benzathin 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 4 ml |
Benzathine benzylpenicillin 600000 unit/mL suspension for injection |
benzylpenicillin, benzathin 900.000 IE/benzylpenicillin, procain 300.000 IE pulver til injektionsvæske, opløsning, hætteglas |
Benzathine benzylpenicillin 900000 unit/mL and procaine benzylpenicillin 300000 unit/mL suspension for injection |
benzylpenicillin, procain 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 1 ml |
Product containing precisely procaine benzylpenicillin 600000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
benzylpenicillin, procain 600.000 enheder/ml injektionsvæske, suspension, hætteglas a 4 ml |
Product containing precisely procaine benzylpenicillin 600000 unit/1 milliliter conventional release suspension for injection (clinical drug) |
Penicillin poisoning NOS |
Poisoning caused by penicillin (disorder) |
Penicillin v potassium 500mg |
Product containing precisely phenoxymethylpenicillin (as phenoxymethylpenicillin potassium) 500 milligram/1 each conventional release oral tablet (clinical drug) |
phenoxymethylpenicillinkalium tablet 500 mg |
Product containing precisely phenoxymethylpenicillin (as phenoxymethylpenicillin potassium) 500 milligram/1 each conventional release oral tablet (clinical drug) |
Penicillium mycetogenum |
Penicillium mycetomagenum |
Penicillium patulum |
Penicillium griseofulvum |
Penicillium rubrum |
Talaromyces purpureogenus (organism) |
Penicillium rubrum toxicosis |
Penicillium purpurogenum toxicosis (disorder) |
Penicilloyl G-ekstrakt |
Product containing benzylpenicillin (medicinal product) |
penicilloyl V-ekstrakt |
Phenoxymethylpenicillin-containing product |
Penile disorders NOS |
Disorder of penis |
Penile disorders NOS |
Disorder of penis |
Pentamidine isethionate 300mg injection |
Pentamidine isetionate 300 mg powder for solution for injection vial |
pentamidinisethionat 300 mg/5 ml inhalationsvæske til nebulisator, opløsning |
Product containing precisely pentamidine isethionate 60 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
Pentamidine isethionate 300mg/vial injection |
Pentamidine isetionate 300 mg powder for solution for injection vial |
Pentasa 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
Pentastivelse 10 % infusionsvæske, opløsning, flaske |
Pentastarch 100 mg/mL solution for injection |
Pentastivelse 10 % injektionsvæske, opløsning, pose |
Pentastarch 100 mg/mL solution for injection |
Pentastarch 10g/100mL conventional release solution for infusion 500mL bag |
Pentastarch 100 mg/mL solution for injection |
Pentastarch 10g/100mL injection |
Pentastarch 100 mg/mL solution for injection |
pentastivelse 10 mg/100 ml infusionsvæske, opløsning, pose a 500 ml |
Pentastarch 100 mg/mL solution for injection |
Pentastarch 6% in sodium chloride 7.2% conventional release solution for injection |
Product containing only pentastarch (medicinal product) |
Pentastivelse 6 % i natriumchlorid 7,2 % infusionsvæske, opløsning |
Product containing only pentastarch (medicinal product) |
Pentastivelse 6 % infusionsvæske, opløsning, flaske |
Product containing precisely pentastarch 60 milligram/1 milliliter conventional release solution for injection (clinical drug) |
allergi over for pentastivelse |
Non-allergic hypersensitivity to pentastarch |
pentobarbitalnatrium 18,2 mg/5 ml eliksir |
Product containing precisely pentobarbital sodium 3.64 milligram/1 milliliter conventional release oral solution (clinical drug) |
pentobarbitalnatrium 20 mg/5 ml eliksir |
Pentobarbital sodium 4 mg/mL oral solution |
Pentose shunt pathway |
Pentose shunt pathway |
Pentostatin 10mg injection |
Pentostatin 10 mg powder for solution for injection vial |
Pentosyltransferase |
Pentosyltransferase |
People's democratic republic of Yemen |
Yemen (geographic location) |
pepsinspecifikt ekstrakt |
Product containing pepsin A (medicinal product) |